APA (7th ed.) Citation

Tzogani, K., & Mickisch, G. (2015). The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. The oncologist, 20(2), . https://doi.org/10.1634/theoncologist.2014-0177

Chicago Style (17th ed.) Citation

Tzogani, Kyriaki, and Gerald Mickisch. "The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior Treatment with Sunitinib or a Cytokine: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use." The Oncologist 20, no. 2 (2015). https://doi.org/10.1634/theoncologist.2014-0177.

MLA (9th ed.) Citation

Tzogani, Kyriaki, and Gerald Mickisch. "The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior Treatment with Sunitinib or a Cytokine: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use." The Oncologist, vol. 20, no. 2, 2015, https://doi.org/10.1634/theoncologist.2014-0177.